Stocks News

LAST PRICE
45.2100
TODAY'S CHANGE (%)
Trending Down-1.1800 (-2.5437%)

Bid / Lots
45.0000/ 1
Ask / Lots
45.5000/ 2
Open / Previous Close
46.1300 / 46.3900
Day Range
Low 45.1900
High 46.9250
52 Week Range
Low 7.7900
High 65.6000
Volume
534,619
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Janux Therapeutics Insider Sold Shares Worth $1,289,879, According to a Recent SEC Filing, from 16 hours ago by MT Newswires
  16 hours ago by MT Newswires
  Companies Mentioned: JANX
  03:20 AM EST, 11/29/2024 (MT Newswires) -- David Alan Campbell, Director, President and Chief Executive Officer, on November 25, 2024, sold 25,000 shares in Janux Therapeutics (JANX) for $1,289,879. Following the Form 4 filing with the SEC, Campbell...
Nov 25, 2024
- Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies, from 9:00AM ET on Monday Nov 25, 2024 by Dow Jones
  9:00AM ET on Monday Nov 25, 2024 by Dow Jones
  Companies Mentioned: JANX
  
  Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
  
  The virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET
Nov 22, 2024
- DJ Janux Therapeutics Initiated at Outperform by Leerink Partners, from 8:20AM ET on Friday Nov 22, 2024 by Dow Jones
  8:20AM ET on Friday Nov 22, 2024 by Dow Jones
  Companies Mentioned: JANX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/JANX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 22, 2024 08:20 ET (13:20 GMT)
- Leerink Initiates Janux Therapeutics at Outperform With $79 Price Target, from 7:14AM ET on Friday Nov 22, 2024 by MT Newswires
  7:14AM ET on Friday Nov 22, 2024 by MT Newswires
  Companies Mentioned: JANX
  07:14 AM EST, 11/22/2024 (MT Newswires) -- Janux Therapeutics (JANX) has an average rating of buy and mean price target of $66.10, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks...
Nov 15, 2024
- DJ 13D Filings -- Barron's, from 9:30PM ET on Friday Nov 15, 2024 by Dow Jones
  9:30PM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: PBF, VTOL, JANX, BTDR, PI
  
  These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 7 through Nov. 13, 2024. Source: VerityData

Yesterday
- *DJ H. Lundbeck: Longboard Pharmaceuticals Acquisition Expected to Close on Dec 2, from 2:06AM ET on Thursday Nov 28, 2024 by Dow Jones
  2:06AM ET on Thursday Nov 28, 2024 by Dow Jones
  Companies Mentioned: LBPH
Nov 27, 2024
- Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference, from 9:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  9:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: GERN
- Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference, from 8:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  8:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: SLNO
Nov 26, 2024
- Soleno Therapeutics Says FDA Extends DCCR NDA Review Citing 'Major Amendment', from 9:03AM ET on Tuesday Nov 26, 2024 by MT Newswires
  9:03AM ET on Tuesday Nov 26, 2024 by MT Newswires
  Companies Mentioned: SLNO
- Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome, from 8:30AM ET on Tuesday Nov 26, 2024 by Dow Jones
  8:30AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: SLNO
- Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences, from 8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: KROS
Nov 21, 2024
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Thursday Nov 21, 2024 by Dow Jones
  4:30PM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: GERN
Nov 20, 2024
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of MARX, BRKH, MNTX and LPBH, from 6:06PM ET on Wednesday Nov 20, 2024 by Dow Jones
  6:06PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: MNTX, LBPH, BRKH, MARX
Nov 14, 2024
- Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: SLNO
Nov 12, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders, from 1:20PM ET on Tuesday Nov 12, 2024 by PR Newswire
  1:20PM ET on Tuesday Nov 12, 2024 by PR Newswire
  Companies Mentioned: ZUO, B, LBPH

Janux Therapeutics Inc
NASDAQ:JANXUnited States

Search Criteria

Today

Janux Therapeutics Insider Sold Shares Worth $1,289,879, According to a Recent SEC Filing, from 16 hours ago by MT Newswires

Nov 25, 2024

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies, from 9:00AM ET on Monday Nov 25, 2024 by Dow Jones

Nov 22, 2024

DJ Janux Therapeutics Initiated at Outperform by Leerink Partners, from 8:20AM ET on Friday Nov 22, 2024 by Dow Jones

Leerink Initiates Janux Therapeutics at Outperform With $79 Price Target, from 7:14AM ET on Friday Nov 22, 2024 by MT Newswires

Nov 15, 2024

DJ 13D Filings -- Barron's, from 9:30PM ET on Friday Nov 15, 2024 by Dow Jones

Peers Headlines

Yesterday

*DJ H. Lundbeck: Longboard Pharmaceuticals Acquisition Expected to Close on Dec 2, from 2:06AM ET on Thursday Nov 28, 2024 by Dow Jones

Nov 27, 2024

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference, from 9:00AM ET on Wednesday Nov 27, 2024 by Dow Jones

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference, from 8:00AM ET on Wednesday Nov 27, 2024 by Dow Jones

Nov 26, 2024

Soleno Therapeutics Says FDA Extends DCCR NDA Review Citing 'Major Amendment', from 9:03AM ET on Tuesday Nov 26, 2024 by MT Newswires

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome, from 8:30AM ET on Tuesday Nov 26, 2024 by Dow Jones

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences, from 8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones

Nov 21, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 20, 2024

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of MARX, BRKH, MNTX and LPBH, from 6:06PM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 14, 2024

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 12, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders, from 1:20PM ET on Tuesday Nov 12, 2024 by PR Newswire